I blogged here exploring models of innovation funding generates the greatest bang for the buck in terms of achieving the primary objective of catalysing innovation. This post will provide some analytical frameworks to formulate a policy on innovation funding. This (on the importance of portfolio management activities), this (on an industrial policy for funding startup innovation largely through grants), and this (on the success of Maharashtra’s Defence and Aerospace Fund) are other recent blogs on the topic. This post will summarise all the takeaways and outline some guidance on startup innovation funding.
The policy objective of startup financing is fundamentally to expand the envelope of investible startups and innovations and thereby crowd-in private risk capital. What is the best approach to achieve this objective?
Answering the question requires addressing the challenge of whether public innovation funding primarily expands the investable universe (genuine additionality) or primarily subsidises returns on investments that would have happened anyway (return-amplification / crowding-in of already-attracted capital).
In the context of infrastructure, I have written here arguing that India’s efforts to crowd-in private capital into infrastructure sectors through the likes of IIFCL and NIIF, and IDFC earlier, have struggled to deliver the additionality (in terms of derisking sectors outside the traditional strongholds of public private partnerships) as the new institutions have ended up competing with the private sector for investments.
What does the empirical evidence on these efforts globally report?
A useful framework for thinking about this would be to categorise funding into three buckets: seed/angel stage (one that leads to proof of concept and lab validation, TRL 2-4), technology/product development stage (includes prototypes and pilots, TRL 4-7), and commercial scaling stage (TRL 7-9). The first category is pure incubation of ideas through grants; the second is about expanding the pool of scalable innovations; and the third is about derisking and crowding in private capital to scale innovations.
The first stage, being the riskiest, will have the greatest additionality from public funding. It is invariably grant-funded, and gets the biggest share of public funding focus across countries, also because it is essential to create the pipeline of startups that can be feedstock for VCs and other investors. It is no good to have a VC ecosystem without a strong investible startup pipeline in the prioritised technologies.
In the second stage, being the “innovation valley of death”, grants may be the best option. While instruments such as a Simple Agreement for Future Equity (SAFE), popularised by Y Combinator, and other forms of convertible funding are commonly discussed in the context of technology/product development, the evidence from successful global cases points to grants, with at best hybrid forms like clawbacks or profit sharing. Interestingly, apart from India (BIRAC and MEITY MSH), no major country uses SAFE in public funding.
This is because while investors obviously favour equity instruments like SAFE in pure private market contexts, they create problems with the determination of future cap tables, significantly diluting entrepreneurs and diminishing their incentives at so early a stage of the startup’s journey, and also making them significantly unattractive for commercial investors (who generally prefer startups without the encumbrances from public shareholding).
It can be observed that those with risk capital instruments tend to kick in only at the TRL 6-7 stages.
In this context, it is worth briefly discussing the critiques of grant funding to startups. Those who critique giving grants to startups do not realise the central role of public funding in deepening the innovation ecosystem for commercial capital to then come in. In countries like India, where early-stage risk capital is tiny, public funding is critical to create a deep and broad pipeline of innovations. The concern of possible incentive distortions from giving away free money is largely minimised through milestone-based tranches or conditional grants. Critics also tend to conflate these two categories of funding with the third stage of commercial scaling capital, which we now turn to.
The dilemma between expanding the pool of capital and returns-amplification is most relevant to this stage of commercial scaling capital. The global evidence on this is mixed. The Israeli Yozma program, which deployed funds through Fund of Funds (FoFs), is thought to have catalysed the country’s vibrant VC industry.
However, other examples point to returns-amplification. A study of IFC’s blended finance deals in the 2000-20 period finds comparable financial returns to non-blended projects but “no statistically significant excess private mobilisation beyond what IFC’s standard lending would attract.” In other words, blending did not increase the quantum of private investment — it redistributed risk between IFC and private co-investors.
This finding is echoed in a 2023 study of SIDBI’s Fund of Funds for Startups (FFS) 1.0 by the Impact and Policy Research Institute (IMPRI), India’s Startup Engine: A Policy Review of the Fund of Funds Initiative. It finds that most FFS 1.0 capital went to established VC funds that would have raised capital independently. It also found “crowding-in effect was primarily reputation/signal, not financial additionality,” the government’s involvement functioned more as a validation of fund managers to private investors than as a necessary injection of capital. While FFS 1.0 delivered a 2x mobilisation ratio, it was mostly in already-functioning VC markets.
This brings us to the question of the most cost-effective approach to achieve the public finance objective while supporting commercial scaling. The options span the spectrum from directly investing in the startup to indirectly investing through FoFs.
While the former allows for targeting the riskiest innovations/startups, it creates the challenge of due diligence, which can be addressed through co-investment with professional investors that piggyback on their diligence. While the latter limits the control over who/what is funded, it allows full play for professional investment practices.
In either case, the nature of the entity that deploys the public funds is important. A fully public or majority public shareholding corporation, whether non-profit or for-profit, will struggle to deploy risk capital and will be hobbled by the restraints of the General Financial Rules (GFR) and the vigilance from oversight agencies. It is for this reason that there is no instance from India of a government-owned entity directly making risk capital investments (apart from the Maharashtra Defence and Aerospace Fund). Its alternative, a majority privately owned entity or a Category I Alternative Investment Fund (AIF) with private Limited Partners (LPs), cannot avoid the returns-amplification problem.
In the circumstances, the most prudent and effective strategy would be the FoFs route with some sharply defined conditionalities. The funds could be committed at concessional terms - subordinate equity, first loss buffer to a certain threshold, capped returns, warrants with lower liquidation preference, etc. It should be complemented by broad mandates on the nature of investments made, specifically on the TRL stages of the innovations, and pre-defined technology areas.
When public capital is subordinated to private capital in the waterfall through any of the aforesaid approaches, the public subsidy is targeted precisely at the risk premium that blocks private investment. Return-amplification is minimised because private investors bear disproportionate upside — they are not getting a free subsidy on already-viable deals.
In this context, the RDIF is instructive. For a start, all its funding is debt or equity and only for TRL 4 and above stages. It has three modes of investing based on where it stands in the returns waterfall. In the first mode, RDIF effectively absorbs the first losses and receives distributions after private investors have received their hurdle rate. In the second mode, it receives distributions pari passu with other contributors at the same hurdle rate and IRR. In the third mode, it receives distributions at a higher priority or higher IRR than private contributors.
While the first mode is a good example of concessional lending as discussed above, the second and third modes may need to be justified on other considerations. Scarce public capital should flow to those areas where it has the highest additionality. While it prescribes the broad areas of investing, it may not suffice in pre-empting returns-amplification investing.
In the circumstances, the RDIF runs the risk of ending up with the same problems as those with the likes of IDFC and NIIF in infrastructure (whose portfolios clearly indicate that they tend to compete and crowd-out rather than crowd-in private capital). It may struggle to realise the promised additionality. For instance, it is most likely that most of the funding will flow into the TRL 8-9 innovators in the less risky among the defined areas. Finally, I’m not sure how Focused Research Organisations (FRO) can deploy returnable capital in startups, unless they merely act as pass-throughs to FoFs.
If the second-level fund managers (SLFMs) of RDIF are required to meet additionality criteria (invest in TRL 6-9 companies they would not otherwise fund; report on portfolio-level additionality; face consequences for drift towards safe/commercial deals), the public mandate will be preserved. But without this discipline, every SLFM will cherry-pick the best deals, and the public capital risks becoming a subsidy for private returns. At best, public capital ends up competing with private capital and marginally expanding the large enough and growing pool of risk capital.
Finally, the biggest constraint to scaling is finding the deployment platform in a country where the indigenous product ecosystem, especially domestic OEMs, is very limited. In the circumstances, public policy must play an important role in value addition by facilitating the creation of scaling pathways. This could be through direct procurements (solar cells, smart meters, street lighting LEDs, etc.) or domestic content mandates (cameras, telecom equipment, etc.). This has been a very important pathway for commercial scaling in both the advanced countries and in China, but it will be a challenge for India’s public policy. It is also for this reason that investors should pursue proactive portfolio management in terms of actively facilitating the linking of startups with the public procurement pathways.
In conclusion, a few points to be borne in mind. One, grants at Stage 1 (TRL 1-4) are the highest-additionality instrument globally. No other instrument produces a comparable expansion of the investable universe. The evidence is unambiguous. Two, since private capital will remain scarce, public capital is critical to develop the pipeline of risky innovations and startups. Three, this nature of funding and additionality will also largely apply to the stage of technology/product development.
Four, a blended fund with a derisking public tranche and a set of sharply defined target investment-related conditions, is the highest-additionality structured instrument for commercial scaling. The public tranche absorbs the risk premium, and private capital fills behind. Five, government procurement is the highest-additionality instrument for commercial scaling for hardware companies. Procurement creates more private capital crowding-in than any equity instrument, because it proves market demand.
Finally, as public policy interventions to realise the aforesaid objectives, there are perhaps two low-hanging fruits. One, there should be a portal that consolidates all the startups financed by state and central government departments, and it should become the primary universe of the pipeline for risk capital funding. This portal should be tightly integrated with the ecosystems of VCs and other investors. Second, there should be active portfolio management at the level of all departmental funds to facilitate access to larger public risk capital funds like RDIF and SIDBI FFS 2.0. The objective should be to ensure that promising publicly financed innovations do not remain stranded.


























